“We’re drowning in lookalike content.” Where do you actually start?

Q: You’ve worked content roles at three medical-device pharma companies. What’s the most common mistake you see teams make when they try to differentiate?

A: The knee-jerk move is to ramp up content volume, hoping sheer quantity sets you apart. I’ve seen teams double their output—think 40 blog posts a quarter—while competitors do the same. No one wins. Especially in med device-pharma, the result is indistinguishable messaging: “We improve patient outcomes,” “Our device is safe and effective.” That’s wallpaper.

What’s more productive? Start by auditing your existing messaging against 3 nearest competitors using a simple spreadsheet. Score each piece on specificity, proof, and relevance to decision-makers (e.g., procurement managers at IDNs). In one org, we cut 37% of our blog pipeline because it was just echoing Medtronic and Stryker. Frees you up to pursue what’s actually unique.

Diagnosing the “We’re Unique—But No One Notices” Problem

Q: Sometimes teams tell themselves their messaging is differentiated, but the market disagrees. How do you spot that?

A: Internal echo chambers are dangerous. If your sales team can’t give you a crisp, 20-second summary of how you’re different from the top two competitors—a real differentiator, not “our people care more”—that’s diagnostic. Another clue: Prospects ask generic questions on sales calls, not device-specific ones.

Tactic: Run anonymous competitive messaging surveys via Zigpoll, Survicate, or Typeform with actual buyers (not just MQLs). A 2024 Forrester survey showed that 72% of device purchasers ignore email content that “resembles vendor B2B collateral.” One of our teams saw a 40% bounce rate reduction when we reworded product pages to highlight a single differentiator (“first FDA-cleared continuous glucose monitor with remote monitoring for pediatric patients”).

The Table Stakes Trap: “But Everyone Says They’re Safe and Effective”

Q: Safety, efficacy, regulatory compliance... All claimed by everyone. How do you get past that?

A: You can't differentiate on what’s mandatory. Everyone's products clear the same FDA hoops. What worked for us: Quantify claims that seem table stakes, but with evidence the big guys don’t publish. For example, if your device has a 30% faster calibration time, run a blinded HCP test and publish anonymized outcomes.

One team went from 2% to 11% demo-request conversion by surfacing a 22% reduction in false alarms, benchmarked in over 500 ICU installs.

Differentiation Killers: Fatigue, FOMO, and “Best Practices” Gone Wrong

Q: What are the most frequent root causes when differentiation just flops?

A: Three things:

1. Content Fatigue: You’re recycling storylines that worked last year. When your competitors borrow your same format, you get diminishing returns.
2. FOMO Diversion: You chase every new format—podcasts, webinars, TikTok—without a consistent narrative. The message gets diluted.
3. Misapplied “Best Practices”: Copying what “works” for bigger brands, but at your scale, it just looks generic or forced.

Fix: Pause the new formats for a quarter and run a “What’s Unique” workshop with sales, marketing, and field application specialists. Literally ask, “What’s the one thing you wish prospects knew, but they never seem to?” Four times out of five, it’s not on the website.

At one scale-up, this surfaced their remote device onboarding workflow, which let oncology practices go live 8 days faster than Abbott’s system. We built a landing page and case study around that—web leads spiked 6x, and cost-per-acquisition dropped by a third over two quarters.

Practical Steps: A Troubleshooting Checklist

Q: If you’ve diagnosed undifferentiated content, what are your next steps—what works in practice?

A: Here’s our basic troubleshooting sequence for fast-moving medical device companies:

1. Competitor Audit: Inventory 3-5 competitors’ top-converting assets (whitepapers, landing pages, demo decks). Use SimilarWeb or BuiltWith to prioritize what gets actual traffic.
2. Buyer Feedback Loop: For every new asset, get 5-10 pieces of live feedback from end-users—field nurses, procurement, biomed techs—using Zigpoll or 1:1 interviews. Don’t settle for “sounds fine.” Ask what surprised them.
3. Proof-First Messaging: Swap “innovative” for quantifiable, comparative outcomes. Find or create a stat that only you can publish—even if it requires a small in-house study.
4. Regulatory-Compliance Storytelling: Use your regulatory wins as stories, not just badges—e.g., “Our on-label use for pediatrics means X hospital reduced off-label liability by 18% in 2022.”
5. Iterative Testing: Run A/B tests on CTA phrasing, hero copy, and asset format. In one case, moving a single claim (“first device cleared for telehealth companions”) up the page doubled downloads in two weeks.

Caveat: This approach won’t scale if you lack credible proof or can’t get product team buy-in. If your device is genuinely undifferentiated, no amount of copy tinkering will fix it—bring that data to leadership instead.

Benchmarks, Not Buzzwords: Making the Most of Data

Q: Advanced teams want to double down—what’s the pro move for ongoing differentiation?

A: Publish benchmark data nobody else has, even if your numbers aren’t perfect. Run blinded pilot studies, publish anonymized outcomes, or aggregate post-market surveillance in a yearly report. In pharmaceuticals, hospitals crave comparative performance data. A 2024 KLAS survey showed 59% of buyers value “transparent, third-party outcomes” over peer testimonials.

We once published an anonymized device recall rate comparison, which was 0.14% vs. an industry average of 0.22%. Not a jaw-dropping delta, but specific. That single graph made it into every procurement call for two quarters.

“Where does this fall down?”—The Limitations

Q: Any real-world “gotchas” or situations where these fixes don’t deliver?

A: Several:

• Market Saturation: If your segment’s truly commoditized (e.g., catheters or basic infusion pumps), even the sharpest proof points can get lost. Sometimes you need to shift category or persona.
• Regulatory Handcuffs: For anything pre-market or still in pivotal trial, you’re stuck. Overpromising or publishing “aspirational” claims opens compliance risk.
• Bandwidth: If you don’t have buy-in from product, sales, or regulatory, differentiation projects stall. I’ve seen too many content teams run rogue, only to have their best headlines nixed at the last minute.

Last Word: Action Items That Actually Move the Needle

Q: For a mid-level content marketer, what are three practical moves to start this week?

A: If you do one thing, it’s this: ruthlessly prune your messaging down to one headline differentiator per campaign. Don’t try to win on every front.

Second: Pull 5 competitive assets and annotate what they prove versus what they claim. If you can out-data them, do so.

Third: Get buyer feedback via Zigpoll, Survicate, or in-person, and veto anything that “sounds like everyone else.”

If you do those three, your next campaign will stand out. And you’ll spend a lot less time defending “why we’re different” in meetings.

Bonus: Quick Reference—What to Watch For

If you’re not seeing movement after six weeks, revisit your audit—you’re probably still playing in the table stakes sandbox.

Bottom line: Competitive differentiation is about being specific, credible, and buyer-obsessed. Not louder. Not busier. Prove what only you can say—and watch your numbers change.